Nicholls, Wayne

Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial

Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 357

Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03)

Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., Mahajan, A., Su, J., Bouffet, E., Bartels, U., et al. (2021) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentNeuroblastoma Research and Treatments

Cited by 241

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma

Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology

Sarcoma Diagnosis and TreatmentBone Tumor Diagnosis and Treatments

Cited by 28